Sandoz Acquires Just-Evotec Biologics EU SAS to Boost Biosimilar Leadership

Sandoz Group AG announced the acquisition of Just-Evotec Biologics EU SAS from Evotec SE, thereby strengthening its position in the biosimilars sector. The acquisition includes the Toulouse development site and a perpetual license to cutting-edge continuous-manufacturing technology. This move aligns with Sandoz's strategy to enhance its in-house development and manufacturing capabilities for biosimilars.

The acquisition is strategic for capturing the projected over USD 300 billion biosimilars market opportunity expected over the next decade. It integrates with Sandoz's investments in Europe, forming a comprehensive biosimilars network. Sandoz's CEO, Richard Saynor, highlighted that the acquisition marks a pivotal step toward maintaining the company's leadership in biosimilars.

The deal does not affect the company's 2025 financial guidance and complements Sandoz's existing commitments in Slovenia. JEB SAS employees have seamlessly transitioned to Sandoz, reinforcing the company's commitment to expanding access to affordable biologics globally.